Novavax's Nuvaxovid Receives Full Marketing Authorization In The EU For The Prevention Of COVID
Portfolio Pulse from Happy Mohamed
Novavax, Inc. (NASDAQ:NVAX) has received full Marketing Authorization (MA) from the European Commission for its COVID-19 vaccine, Nuvaxovid. The vaccine is now fully authorized for use as a primary series in individuals aged 12 and older and as a booster dose in adults aged 18 and older. The company is also preparing to file for full approval in the U.S. and other markets.
July 06, 2023 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's full Marketing Authorization in the EU for its COVID-19 vaccine could potentially boost the company's stock in the short term. The company's plans to file for full approval in the U.S. and other markets could also have a positive impact.
The full Marketing Authorization in the EU is a significant milestone for Novavax, which could lead to increased sales and revenues. The company's plans to seek full approval in the U.S. and other markets also indicate potential for further growth.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100